Decay accelerating factor (CD55): a target for cancer vaccines?
作者： Ian Spendlove , Lindy G. Durrant , Li Li , James Carmichael
DOI:
关键词:
摘要: The 791Tgp72 antigen has been used successfully as a target for tumor imaging and T-cell immunotherapy. We have characterized this using the monoclonal antibody 791T/36 72/66 kDa doublet. NH 2 -terminal protein sequencing of two bands revealed identity with complement regulatory CD55. Antibodies recognizing different domains CD55 were also shown to bind purified 791Tgp72, although sequence analysis cDNA cloned from 791T cells showed 100% homology transfection into antigen-negative CHO resulted in binding 791T/36. This identifies protects attack; however, it can transduce signals lymphocytes is ligand CD97, expressed by activated T cells. These results suggest that plays roll signaling between innate adaptive immune responses. It therefore very intriguing target, because absence molecule makes susceptible complement, whereas protective overexpression being
aacrjournals.org参考文章(31)
L G Durrant, R A Marksman, K Grant, R Rodvien, R A Robins, P J Scannon, R W Baldwin, V S Byers, Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clinical and Experimental Immunology. ,vol. 75, pp. 258- 264 ,(1989)
Declan T.J. Buckley, Adrian R. Robinst, Lindy G. Durrant, Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Human antibodies and hybridomas. ,vol. 6, pp. 68- 72 ,(1995) , 10.3233/HAB-1995-6205
P. E. Lipsky, S. S. Patel, Laurie S Davis, J. P. Atkinson, Decay-accelerating factor functions as a signal transducing molecule for human T cells Journal of Immunology. ,vol. 141, pp. 2246- 2252 ,(1988)
L. G. Durrant, J. D. Hardcastle, R. A. Robins, G. W. L. Denton, T. J. D. Buckley, H. F. Sewell, Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7 Cancer Research. ,vol. 54, pp. 4837- 4840 ,(1994)
M. Kathryn Uszewski, Timothy C. Farries, Douglas M. Lublin, Isabelle A. Rooney, John P. Atkinson, Control of the complement system. Advances in Immunology. ,vol. 61, pp. 201- 283 ,(1996) , 10.1016/S0065-2776(08)60868-8
R W Finberg, A Nicholson-Weller, W White, Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. Journal of Immunology. ,vol. 149, pp. 2055- 2060 ,(1992)
Lindy G. Durrant, Jack D. Hardcastle, R. Adrian Robins, Robert W. Baldwin, Anthony Brown, Nicholas C. Armitage, Association of antigen expression and DNA ploidy in human colorectal tumors. Cancer Research. ,vol. 46, pp. 3543- 3549 ,(1986)
A S Shaw, T Fujita, J Kwong, M W Olszowy, A M Shenoy-Scaria, D M Lublin, Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. Journal of Immunology. ,vol. 149, pp. 3535- 3541 ,(1992)
D. J. Anstee, T. Kinoshita, K. E. Coyne, W. Rosse, E. Scott Thompson, S. E. Hall, D. M. Lublin, T. Fujita, M. A. Arce, Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. Journal of Immunology. ,vol. 149, pp. 2906- 2913 ,(1992)
Nicholson-Weller A, Wang Ce, Structure and function of decay accelerating factor CD55. Journal of Laboratory and Clinical Medicine. ,vol. 123, pp. 485- 491 ,(1994)